

Haematologica
HAEMATOL/2019/240853
Version 1

Are NGS results knocking on Heaven's door for
transplantation-planning in chronic myelomonocytic leukemia?

Guillermo F. Sanz, Mariam Ibañez, and Elvira Mora

Disclosures: 1. FUNDING/ACKNOWLEDGEMENTS This study was supported by research funding from Innovative Medicines Initiative 2 Joint Undertaking under HARMONY Grant Agreement nº 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Program and EFPIA; FEDER funds (CIBERONC (CB16/12/00284)), "Fundación Española de Hematología (FEHH)"; "Instituto de Salud Carlos III" grants PI16/011113, PI16/00665 and PI18/01472; and from the "Consellería de Educación, Cultura y Deporte" PROMETEOII/2015/008 and GVA/2018//004. 2. CONFLICTS OF INTEREST DISCLOSURE Conflict-of-interest disclosure: G.F.S. has received honoraria from and/or played an advisory role for AbbVie, Amgen, Böehringer-Ingelheim, Celgene, Helsinn Healthcare, Hoffmann-La Roche, Janssen-Cilag, Novartis, Onconova, and Takeda. E.M. has received honoraria from and/or played an advisory role for Alexion, Amgen, Novartis and Sanofi Genzyme. G.F.S., M.I., and E.M. work at Hospital Universitario y Politécnico La Fe and Instituto de Investigación Sanitaria La Fe, which receive research funding and/or participate in multiple clinical trials funded by different pharmaceutical companies, including AbbVie, Amgen, Böehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Helsinn Healthcare, Hoffman-La Roche, Janssen-Cilag, Novartis, Takeda, and Onconova. G.F.S., M.I., and E.M. are also members of the Spanish Group on Myelodysplastic Syndromes (Grupo Español de Síndromes Mielodisplásicos), which is sponsored by Celgene and Novartis. 3. NOT APPLICABLE

Contributions: G.F.S conceived, supervised, and wrote the paper; and M.I. and E.M. wrote the paper. All authors approved the final submitted version.